CDC intends to issue a sole source modification to University of Texas under contract 200-2000-10042 to conduct antimicrobial susceptibility testing on all isolates confirmed to be Streptococcus pneumoniae, Group A streptococcus (GAS) , Group B streptococcus (GBS) through the Active Bacterial Core surveillance (ABCs) program of CDCs Emerging Infections Program Network. ABCs is used to follow trends in disease rates, to assess the effectiveness of public health interventions (e.g., vaccination), and to conduct special epidemiologic and laboratory studies. The contractor is required to: (1) confirm identification of isolates as Streptococcus pneumoniae, GAS, or GBS; (2) store all isolates in a manner that will ensure future viability. The isolates will be received from the CDC Streptococcal laboratory or directly from surveillance sites collaborating with CDC. Isolates received from surveillance sites then need to be shipped to CDC for additional characterization, e.g., serotyping; (3) ship additional subcultures of each isolate to the CDC and ATSDR Specimen Packaging, Inventory and Repository (CASPIR) for permanent storage; (4) Perform antimicrobial susceptibility testing of S. pneumoniae, GAS, and GBS. The period of performance will commence September 29, 2005 through December 31, 2005. The point of contact for this procurement is Teri Routh-Murphy, Centers for Disease Control and Prevention, 2920 Brandywine Road, MS-K14, Room 3622, Atlanta, GA 30341 or email: tnr3@cdc. No telephone calls will be accepted. Numbered Note 22.

Bid Protests Not Available